Exenatide For Reducing the Reinforcing Effects of Cocaine

Summary

This study will determine the safety and tolerability of exenatide (Bydureon®) as a pharmacotherapy for cocaine use disorder. An inpatient human laboratory study will be conducted in which the self-administration of cocaine, as well as the subjective and physiological effects of cocaine, are evaluated during maintenance on placebo and exenatide. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by the FDA to treat cocaine use; therefore, it is called an investigational drug.

Timeline

Start

2024-08-01

Primary completion

2026-03-01

Completion

2026-12-31

Outcome

Outcome not reported

Stopped: “The study was closed due to the inability to acquire the study drug.”

Drugs

Indications